Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Abramson Cancer Center at Penn Medicine350 enrolled

Overview

The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Enrollment

350

Conditions

BRCA1/2 Negative

Interventions

QuestionnairesOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Women and men (at least 18 YO) 2. English speaking AND 3. Negative for BRCA1 and BRCA2 mutations Exclusion Criteria: 1\. Non English speaking patients

Locations (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Completion of questionnaires

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.